Use of long-read nanopore sequencing and short-read whole genome sequencing to resolve individuals with antithrombin deficiency, a rare disease which increase the risk of thrombosis, with unknown molecular base.

This project aims to resolve by nanopore sequencing patients with antithrombin deficiency, a rare disease which significantly increase the risk of thrombosis, in patients with no mutation detected to date in order to fully characterise them.